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S U M M A R Y
The clinical ﬁndings of a pregnant woman from Colombia with a triple co-infection caused by dengue,
chikungunya, and Zika viruses are described. Weekly obstetric ultrasounds from 14.6 to 29 weeks of
gestation were normal. She remains under follow-up and management according to the standard
guidelines for the management of Zika virus-infected pregnant women.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Dengue virus (DENV), chikungunya virus (CHIKV), and Zika
virus (ZIKV) are arboviruses that cause ongoing epidemics in
several countries of Latin America and the Paciﬁc.1,2 CHIKV, DENV,
and ZIKV affect pregnancies, with a wide observed spectrum of
outcomes. Adverse outcomes of CHIKV infections in pregnancy
have been reported in Colombia and on the island of La Re´union,
primarily encephalopathy.3 Severe dengue has been reported in
pregnant women.4 There is a growing body of evidence suggesting
that ZIKV is responsible for severe congenital complications mainly
consisting of microcephaly.5 The extent of congenital complica-
tions related to ZIKV is, however, still a matter of debate,* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).principally because only a small proportion of cases have been
investigated fully.5
Co-infections with these three viruses have been reported,6 but
the effect of co-infections during pregnancy is unknown. In
addition, in the context of the current ZIKV outbreak, which has
become the focus of much attention, other pathogens with a
potential impact in pregnancy may receive less attention. The case
of a pregnant woman with molecular conﬁrmation of a triple co-
infection caused by DENV, CHIKV, and ZIKV is reported herein.
2. Case report
A 33-year-old woman from Sincelejo, Sucre, Colombia, an area
known to have active co-circulation of DENV serotypes 1–4, CHIKV,
and ZIKV,6 presented at 14.6 weeks of her third pregnancy with a
clinical illness, that consist of non-purulent bilateral conjunctivitis,
an intense pruritic maculopapular rash on the upper limbs, thorax,
and abdomen, a headache, mild-to-intense bilateral metacarpo-
phalangeal and wrist arthralgia, and limb edema, particularly ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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orbital pain, hemorrhages, or abdominal pain. She reported that
arboviral infections had not affected her or her family.
The patient had previously been referred with a provisional
diagnosis of mitral valve prolapse in 2013. She had normal
electrocardiogram ﬁndings, and an echocardiogram conﬁrmed the
diagnosis. She had a history of umbilical hernia in 2012 and
cholecystitis in 2015, leading to a cholecystectomy. She had a
single spontaneous abortion in early 2014 and had previously
given birth to a healthy female infant by uncomplicated vaginal
delivery in 2007. She did not report any history of blood
transfusion or organ transplant.Figure 1. Findings in the pregnant woman from Colombia co-infected with Zika (ZIKV), d
showing no alterations. (b) Agarose gel analysis of PCR products for DENV, CHIKV, and ZIK
of infected cultures). (c) Phylogenetic analysis of nucleic acid sequences was performed u
the complete genomes are given. The tree was inferred using the maximum likelihood 
numbers shown to the left of the nodes represent bootstrap support values (1000 replThick and thin blood smears for malaria were negative. Physical
examination revealed cervical lymphadenopathy, non-purulent
conjunctivitis, bipalpebral edema, and painful edema in the lower
limbs, with an extensive maculopapular rash affecting the upper
and lower limbs and abdomen, with Pastia lines (Thompson’s sign).
She did not have hepatomegaly or splenomegaly, either clinically or
on ultrasound, either at presentation or during follow-up
(Figure 1a). Her pulse rate was 88 beats/min, blood pressure was
100/60 mmHg, and temperature was 36.7 8C. A holosystolic
murmur was heard on cardiac auscultation. A neurological
examination was normal. Obstetric ultrasound ﬁndings were
normal for gestational age, with a biparietal diameter ofengue (DENV), and chikungunya (CHIKV). (a) Ultrasounds at 29 weeks of gestation,
V (067, patient samples; C(), negative control; C(+), positive control, supernatants
sing 250 nucleotides of the ZIKV envelope protein. GenBank accession numbers for
algorithm based on the Tamura-parameter model as implemented in MEGA 6. The
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and fetal heart rate of 144 beats/min, with a grade 1 anterior
placenta, no physical abnormalities, and all four cardiac chambers
noted. She was mildly anemic with a hemoglobin of 11.5 g/dl
(normal range 12.0–14.5 g/dl) and lymphopenic with a lymphocyte
count of 1.03  109 cells/l (normal range 1.2–3.2  109 cells/l). She
had an elevated erythrocyte sedimentation rate (ESR) (45 mm/1 h,
normal range 1–15 mm/1 h), a normal creatine phosphokinase level
(57 IU/l, normal range 26–140 IU/l), and normal transaminase levels
(aspartate aminotransferase (AST) 40 IU/l, normal range 10–40 IU/l;
alanine aminotransferase (ALT) 56 IU/l, normal range 7–56 IU/l).
A blood sample was collected on day 3 after the onset of
symptoms for virological analysis to detect DENV, CHIKV, and ZIKV
RNA. A triple nested reverse transcription (RT) PCR was used to
amplify DENV-2, Asian genotype CHIKV, and Asian lineage ZIKV
RNA (Figure 1b). The speciﬁcity of the ampliﬁcation was conﬁrmed
by sequencing. The phylogenetic tree is shown in Figure 1c. The
ampliﬁcation protocol is described in the Appendix.
The patient was initially managed with acetaminophen
(500 mg every 6 h), loratadine (10 mg every 24 h), 10-min ice
massages applied to painful areas and 20-min use of heat pads
(every 1 h), topical calamine (every 6 h), and folic acid (5 mg every
8 h). Subsequently, at 10 days, most of the clinical manifestations
had subsided, except for the wrist arthralgia and skin rash (these
had improved signiﬁcantly 9 weeks later). Her ESR decreased to
17 mm. Weekly obstetric ultrasounds from 14.6 weeks to 29 weeks
of gestation were normal. The patient remains under follow-up
and management according to the standard national and
international protocols, particularly for Zika during pregnancy.
3. Discussion
The clinical presentation of ZIKV infections is non-speciﬁc.
ZIKV infections may be confused with infections caused by other
arboviruses that co-circulate in ZIKV endemic areas, especially
DENV and CHIKV.2 Co-infection of ZIKV and other arboviruses has
already been reported: with DENV and CHIKV in Colombia,6 and
with DENV in French Polynesia and New Caledonia.2 However, it
appears that arbovirus co-infection during pregnancy has not
been reported previously. The impact of arbovirus co-infection on
patient outcomes is unknown, but a fatal co-infection with DENV
and CHIKV has been reported in Colombia.7 During pregnancy,
ZIKV may cause severe damage to the fetus but not to the pregnant
woman. However, it is important to recognize maternal DENV
infections because pregnant women are at increased risk of
developing severe dengue.4 It is also important to recognize
CHIKV infections because encephalopathy in neonates has been
associated with CHIKV infections3 and ZIKV infections in
Martinique.8
Several guidelines have been formulated to assist clinicians in
assessing ZIKV in patients with DENV- and CHIKV-negative
samples and in those who are negative on sequential testing for
both pathogens.9,10 However, even if these guidelines are followed,
co-infections may be missed. Where these viruses co-circulate,
especially in the Americas and Paciﬁc, multiplex arbovirus
detection including ZIKV, CHIKV, and DENV should be implemen-
ted for at-risk patients, including pregnant women, employing the
same recommendations that have been issued for the screening of
blood donors.2,11 A commercial multiplex molecular assay
detecting ZIKV, CHIKV, and DENV has recently been accredited
by the US Food and Drug Administration and may be used in
routine practice.
ZIKV is responsible for severe fetal and neonatal complications,
especially microcephaly, but the risk of microcephaly related to
ZIKV has yet to be deﬁned due to reporting bias.12 Several
infections may cause microcephaly, including the pathogensassociated with the teratogenic effect summarized by the acronym
TORCH.5 Unfortunately, TORCH pathogen infections also have non-
speciﬁc clinical presentations and may be asymptomatic. In the
context of the ZIKV outbreak, there is a risk that clinicians will
focus on ZIKV at the expense of other causes of microcephaly.
During ZIKV outbreaks the incidence of the infection may be high.
In French Polynesia, for instance, 2.8% of asymptomatic blood
donors tested positive for ZIKV RNA during that outbreak.2 Even if
ZIKV RNA is detected, other infections should be considered, and
the detection of ZIKV in microcephalic newborns does not exclude
other causes of this malformation. To date there is no speciﬁc
treatment for ZIKV infections during pregnancy, whereas speciﬁc
treatments have been proposed for other TORCH pathogens,
including Toxoplasma and cytomegalovirus.5 Other causes of
microcephaly including genetic factors should also be investigated
carefully to facilitate genetic counseling. ZIKV may cause other
central nervous system malformations that may be found in
TORCH pathogen infections5, and the occurrence of co-infections
should be investigated carefully.
Since the World Health Organization declared the ZIKV
epidemic a Public Health Emergency of International Concern,
the major focus has been on ZIKV – other pathogens have been
neglected. Even if ZIKV RNA is detected, this does not exclude the
possibility of other infections.
Because ZIKV infection clinically resembles DENV and CHIKV
infections, which co-circulate in most of the ZIKV endemic areas
and are also responsible for maternofetal infections, it is
recommended that all symptomatic pregnant women should be
tested for ZIKV, CHIKV, and DENV, even if ZIKV has already been
detected.
Finally, the case presented here suggests that co-infection
should be considered in travelers visiting areas where these
arboviruses co-circulate.
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Appendix
The reverse transcription and ﬁrst ampliﬁcation round (multi-
plex) was performed with three outer oligo pairs and the
SuperScript III One-Step RT-PCR Kit (Invitrogen). The ZIKV outer
primers were designed on gene E: ZF944 50-GGT CAT GAT ACT GCT
GAT TGC, and ZR1269 50-CCA CTA ACG TTC TTT TGC AGA C (which
align with Latin American isolates). CHIKV outer primers were
designed on the E1 gene: CHK-F10240 50-ACG CAA TTG AGC GAA
GCA C, and CHK-R10541 50-CCA AAT TGT CCY GGT CTT CCT (which
have been reported previously). DENV was ampliﬁed using primers
mD1–D2 reported previously.
The second-round ampliﬁcation (nested) was carried out in
separate tubes for each virus using 2 ml of ﬁrst amplicon, the
above-mentioned reverse primers, and a new forward inner primer
annealing inside the amplicon. These inner forward primers were
ZR1241 50-AGT GTC TGA CTG CTT GTC AAG G for ZIKV, CHK-
R10444 50-CTG AAG ACA TTG GCC CCA C for CHIKV. For DENV, a
W.E. Villamil-Go´mez et al. / International Journal of Infectious Diseases 51 (2016) 135–138138mix of the D1 reverse primer and forward primers TS1 50-CCC GTA
ACA CTT TGA TCG C, TS2 50-CGC CAC AAG GGC CAT GAA CAG TTT,
TS3 50-TAA CAT CAT CAT GAG ACA GAG C, and TS4 50-TTC TCC CGT
TCA GGA TGT TC was used. Ampliﬁcation products were separated
by agarose electrophoresis and stained with ethidium bromide.
Positive controls were both culture supernatants of infected C6/36
cells (DENV) or Vero cells (CHIKV) and serum of previously
conﬁrmed infections for DENV, CHIKV, and ZIKV. Supernatant of
non-infected C6/36 and serum from healthy donors were used as
negative controls. ZIKV and CHIKV ampliﬁcation products were
conﬁrmed by sequencing the E encoding gene for ZIKV and the E1
encoding gene for CHIKV (Asian genotype). The second round of
ampliﬁcation identiﬁed DENV serotype 2.
References
1. Rodriguez-Morales AJ. Zika: the new arbovirus threat for Latin America. J Infect
Dev Ctries 2015;9:684–5.
2. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016;29:487–524.
3. Ge´rardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al.
Multidisciplinary prospective study of mother-to-child chikungunya virusinfections on the island of La Re´union. PLoS Med 2008;5:e60. http://
dx.doi.org/10.1371/journal.pmed.0050060
4. Machado CR, Machado ES, Rohloff RD, Azevedo M, Campos DP, de Oliveira RB,
Brasil P. Is pregnancy associated with severe dengue?. A review of data from the
Rio de Janeiro surveillance information system. PLoS Negl Trop Dis
2013;7:e2217.
5. Panchaud A, Stojanov M, Ammerdorffer A, Vouga M. Emerging role of Zika virus
in adverse fetal and neonatal outcomes. Clin Microbiol Rev 2016;29:659–94.
6. Villamil-Go´mez WE, Gonza´lez-Camargo O, Rodriguez-Ayubi J, Zapata-Serpa D,
Rodriguez-Morales AJ. Dengue, chikungunya and Zika co-infection in a patient
from Colombia. J Infect Public Health 2016. http://dx.doi.org/10.1016/j.jiph.20
7. Mercado M, Acosta-Reyes J, Parra E, Pardo L, Rico A, Campo A, et al. Clinical and
histopathological features of fatal cases with dengue and chikungunya virus co-
infection in Colombia, 2014 to 2015. Euro Surveill 2016;21. http://dx.doi.org/
10.2807/1560-7917.ES.2016.21.22.30244. pii=30244.
8. Roze´ B, Najioullah F, Signate A, Apetse K, Brouste Y, Gourgoudou S, et al. Zika
virus detection in cerebrospinal ﬂuid from two patients with encephalopathy,
Martinique, February 2016. Euro Surveill 2016;21. http://dx.doi.org/10.2807/
1560-7917.ES.2016.21.16.30205. pii=30205.
9. World Health Organization. Laboratory testing for Zika virus infection. Interim
guidance 23 March 2016. WHO/ZIKV/LAB/16.1. WHO; 2016.
10. Pan American Health Organization. Algorithm for detecting Zika virus. PAHO;
2016.
11. Musso D, Stramer SL, Bush MP. Zika virus: a new challenge for blood transfu-
sion. Lancet 2016;387:1993–4.
12. Samarasekera U, Triunfol M. Concern over Zika virus grips the world. Lancet
2016;387:521–4.
